Klatskin's Tumor disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: KLT001 MIFTS: 50	Klatskin's Tumor Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Klatskin's Tumor

MalaCards integrated aliases for Klatskin's Tumor:

Name: Klatskin's Tumor ¹² ⁵² ¹⁵ ¹⁷

Klatskin Tumor ¹² ⁵² ⁵⁸ ⁶ ⁴³ ⁷¹

Hilar Cholangiocarcinoma ¹² ⁵⁸ ¹⁷

Perihilar Cholangiocarcinoma ⁵² ⁷¹

Perihilar Extrahepatic Bile Duct Carcinoma ¹²

Hilar Cholangiocellular Carcinoma ¹²

Hilar Cca ⁵⁸

Characteristics:

Orphanet epidemiological data:

⁵⁸

klatskin tumor
Inheritance: Not applicable; Age of onset: Adult; Age of death: adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Liver diseases Gastrointestinal diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Malignant neoplasms of digestive organs

Malignant neoplasm of other and unspecified parts of biliary tract

Malignant neoplasm: Extrahepatic bile duct

Orphanet: ⁵⁸

Rare hepatic diseases

External Ids:

Disease Ontology ¹² DOID:4927

MeSH ⁴³ D018285

NCIt ⁴⁹ C36077

SNOMED-CT ⁶⁷ 6492006

MESH via Orphanet ⁴⁴ D018285

ICD10 via Orphanet ³³ C24.0

UMLS via Orphanet ⁷² C0206702

Orphanet ⁵⁸ ORPHA99978

SNOMED-CT via HPO ⁶⁸ 111293003 161832001 18165001 more

EFO ¹⁷ EFO_1001005 EFO_1001959

UMLS ⁷¹ C0206702 C4045991

Sources

Summaries for Klatskin's Tumor

NIH Rare Diseases : ⁵² Klatskin tumors are are a type of cholangiocarcinoma that begins in an area called the hilum, where the left and right bile ducts join and leave the liver. It is the most common type of cholangiocarcinoma, accounting for more than half of all cases. Symptoms usually don't present until advanced stages of disease, when jaundice is the most common feature. Other symptoms include abdominal pain, unintentional weight loss, and a general feeling of being unwell (malaise ). The cause of Klatskin tumors is unknown. Studies suggest that a combination of genetic, environmental, and lifestyle factors (multifactorial ) likely influence whether a person will develop cholangiocarcinoma. Because Klatskin tumors are often discovered after they have spread, they can be challenging to treat. Surgical removal of the tumor and relief of bile duct blockage are the main goals of treatment.

MalaCards based summary : Klatskin's Tumor, also known as klatskin tumor, is related to sclerosing cholangitis and liver lymphoma, and has symptoms including abdominal pain, icterus and malaise. An important gene associated with Klatskin's Tumor is MIR373 (MicroRNA 373), and among its related pathways/superpathways are Matrix Metalloproteinases and Colorectal Cancer Metastasis. The drugs Bilirubin and Bismuth have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and b cells, and related phenotypes are jaundice and extrahepatic cholestasis

Disease Ontology : ¹² An intrahepatic cholangiocarcinoma arising near or at the confluence of the right and left hepatic ducts.

Wikipedia : ⁷⁴ A Klatskin tumor (or hilar cholangiocarcinoma) is a cholangiocarcinoma (cancer of the biliary tree)... more...

Sources

Related Diseases for Klatskin's Tumor

Diseases related to Klatskin's Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 338)

#	Related Disease	Score	Top Affiliating Genes
1	sclerosing cholangitis	30.9	GPT CEACAM5 ALB
2	liver lymphoma	30.4	CEACAM5 AFP
3	choledocholithiasis	30.2	GPT CEACAM5 ALB
4	biliary tract benign neoplasm	30.2	KRT7 CEACAM5
5	biliary papillomatosis	30.1	KRT7 CEACAM5
6	acute cholangitis	30.1	GPT CEACAM5 ALB
7	hepatic tuberculosis	30.0	GPT ALB
8	cholecystolithiasis	30.0	GPT CEACAM5
9	cholangitis	30.0	GPT CEACAM5 ALB
10	krukenberg carcinoma	29.9	KRT7 CEACAM5
11	appendix adenocarcinoma	29.9	KRT7 CEACAM5
12	pancreatic adenocarcinoma	29.9	MMP9 MMP2 MMP14 APC ALB
13	paralytic ileus	29.8	GPT ALB
14	adenocarcinoma	29.8	MMP9 MMP2 MALAT1 KRT7 CEACAM5 APC
15	cholangitis, primary sclerosing	29.5	PRRT2 PCCA KRT7 GPT ALB
16	intrahepatic cholangiocarcinoma	29.5	KRT7 APC ALB AFP
17	tubular adenocarcinoma	29.5	KRT7 CEACAM5 AFP
18	cystadenoma	29.5	KRT7 CEACAM5 AFP
19	bile duct cystadenocarcinoma	29.3	KRT7 CEACAM5 AFP
20	liver sarcoma	29.3	KRT7 CEACAM5 AFP
21	liver cirrhosis	29.3	MALAT1 GPT ALB AFP
22	viral hepatitis	29.0	GPT ALB AFP
23	cholangiocarcinoma	28.9	MMP9 MIR373 MALAT1 KRT7 CEACAM5 APC
24	gallbladder cancer	28.8	MMP9 MMP2 MALAT1 KRT7 CEACAM5 APC
25	lung cancer susceptibility 3	28.7	MMP9 MMP2 MMP14 MALAT1 KRT7 CEACAM5
26	gastric adenocarcinoma	28.5	MMP9 MMP2 KRT7 CEACAM5 APC AFP
27	bile duct cancer	28.4	MMP2 KRT7 GPT CEACAM5 ALB AFP
28	bile duct adenocarcinoma	27.9	PRRT2 PCCA KRT7 CEACAM5 ALB AFP
29	biliary tract disease	27.7	PRRT2 KRT7 GPT CEACAM5 ALB AFP
30	bile duct disease	27.4	PRRT2 PCCA KRT7 GPT CEACAM5 ALB
31	hepatocellular carcinoma	27.1	MMP9 MMP2 MMP14 MALAT1 KRT7 GPT
32	extracranial arteriovenous malformation	10.6	MMP9 MMP2
33	focal myositis	10.6	MMP9 MMP2
34	lentigo maligna melanoma	10.6	MMP9 MMP2
35	acute transverse myelitis	10.6	MMP9 MMP2
36	transverse myelitis	10.6	MMP9 MMP2
37	nasal cavity squamous cell carcinoma	10.5	MMP9 MMP2
38	multicentric osteolysis-nodulosis-arthropathy spectrum	10.5	MMP2 MMP14
39	spastic entropion	10.5	MMP9 MMP2
40	winchester syndrome	10.5	MMP2 MMP14
41	odontogenic myxoma	10.5	MMP9 MMP2
42	cholestasis	10.4
43	bilirubin metabolic disorder	10.4
44	rare tumor	10.4
45	colon adenoma	10.4	MMP2 MACC1 APC
46	senile ectropion	10.4	MMP9 MMP2
47	light chain deposition disease	10.4	MMP9 MMP2 MMP14
48	aortic aneurysm, familial abdominal, 1	10.4	MMP9 MMP2 MMP14
49	biliary tract cancer	10.3
50	hyperostosis	10.3	MMP9 MMP2 MMP14

Graphical network of the top 20 diseases related to Klatskin's Tumor:

Sources

Symptoms & Phenotypes for Klatskin's Tumor

Human phenotypes related to Klatskin's Tumor:

⁵⁸ ³¹ (show all 10)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	jaundice ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000952
2	extrahepatic cholestasis ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0012334
3	cholangiocarcinoma ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0030153
4	hepatomegaly ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0002240
5	lymphadenopathy ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0002716
6	fatigue ⁵⁸ ³¹	occasional (7.5%)	Occasional (29-5%)	HP:0012378
7	fever ⁵⁸ ³¹	occasional (7.5%)	Occasional (29-5%)	HP:0001945
8	abdominal pain ⁵⁸ ³¹	occasional (7.5%)	Occasional (29-5%)	HP:0002027
9	weight loss ⁵⁸ ³¹	occasional (7.5%)	Occasional (29-5%)	HP:0001824
10	venous thrombosis ⁵⁸ ³¹	occasional (7.5%)	Occasional (29-5%)	HP:0004936

UMLS symptoms related to Klatskin's Tumor:

abdominal pain, icterus, malaise

GenomeRNAi Phenotypes related to Klatskin's Tumor according to GeneCards Suite gene sharing:

²⁶ (show all 11)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-114	9.5	AFP
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	9.5	AFP
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-133	9.5	APC
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-135	9.5	KRT7
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-177	9.5	APC
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-192	9.5	AFP APC KRT7
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-202	9.5	APC
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-29	9.5	AFP APC
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-49	9.5	APC
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	9.5	AFP
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-74	9.5	APC KRT7

MGI Mouse Phenotypes related to Klatskin's Tumor:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	9.1	AFP ALB APC MBD2 MMP2 MMP9

Sources

Drugs & Therapeutics for Klatskin's Tumor

Drugs for Klatskin's Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Bilirubin

Phase 4

635-65-4, 69853-43-6

5280352 21252250

Bismuth

Phase 4

7440-69-9

16682734 105143

Capecitabine

Approved, Investigational

Phase 3

154361-50-9

60953

Trioxsalen

Approved

Phase 3

3902-71-4

5585

s 1 (combination)

Phase 3

Ether

Phase 3

Hematoporphyrins

Phase 3

Hematoporphyrin Derivative

Phase 3

Dermatologic Agents

Phase 3

Dihematoporphyrin Ether

Phase 3

Photosensitizing Agents

Phase 3

Floxuridine

Approved

Phase 1, Phase 2

50-91-9

5790

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239 406563

Trametinib

Approved

Phase 2

871700-17-3

11707110

Levoleucovorin

Approved, Investigational

Phase 2

68538-85-2

Bevacizumab

Approved, Investigational

Phase 1, Phase 2

216974-75-3

Temoporfin

Approved, Investigational

Phase 2

122341-38-2

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

5310940 9887054 6857599 43805

Irinotecan

Approved, Investigational

Phase 2

97682-44-5, 100286-90-6

60838

leucovorin

Approved

Phase 2

58-05-9

6006 143

Cisplatin

Approved

Phase 2

15663-27-1

84093 441203 2767

Gemcitabine

Approved

Phase 2

95058-81-4

60750

Ceritinib

Approved

Phase 2

1032900-25-6

Fluorouracil

Approved

Phase 2

51-21-8

3385

Carboplatin

Approved

Phase 2

41575-94-4

10339178 498142 38904

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Pancrelipase

Approved, Investigational

Phase 2

53608-75-6

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2

59-30-3

6037

Calcium

Approved, Nutraceutical

Phase 2

7440-70-2

271

Erlotinib Hydrochloride

Phase 2

183319-69-9

176871

Trace Elements

Phase 2

Vitamins

Phase 2

Micronutrients

Phase 2

Vitamin B Complex

Phase 2

Vitamin B9

Phase 2

Nutrients

Phase 2

Folate

Phase 2

Calcium, Dietary

Phase 2

Protective Agents

Phase 2

Antidotes

Phase 2

Hormones

Phase 2

Angiogenesis Inhibitors

Phase 1, Phase 2

Antineoplastic Agents, Immunological

Phase 1, Phase 2

Anti-Inflammatory Agents

Phase 2

topoisomerase I inhibitors

Phase 2

Topoisomerase Inhibitors

Phase 2

Antibodies, Monoclonal

Phase 1, Phase 2

Immunoglobulins

Phase 1, Phase 2

Antibodies

Phase 1, Phase 2

Immunologic Factors

Phase 2

Interventional clinical trials:

(show top 50) (show all 54)

#	Name	Status	NCT ID	Phase	Drugs
1	Effect of Preoperative Biliary Drainage on Postoperative Complications in Resectable Patients With Hilar Cholangiocarcinoma(Klatskin Tumor)	Unknown status	NCT00797121	Phase 4
2	Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent: A Randomized Control Trial	Unknown status	NCT00746538	Phase 4
3	Uncovered Self-expandable Metal Stent Versus DoubleLayer Plastic Stent for Malignant Hilar Stricture: a Prospective Randomized Multicenter Trial	Unknown status	NCT01125865	Phase 4
4	Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Unresectable Complex Hilar Cholangiocarcinoma; a Randomized Controlled Trial	Completed	NCT00721175	Phase 4
5	Photodynamic Therapy With S-1 in the Patients With Unresectable Type III or IV Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control	Completed	NCT00869635	Phase 3	S-1 Chemotherapy
6	Sequential Preoperative Ipsilateral Hepatic Vein Embolization After Portal Vein Embolization to Induce Further Liver Regeneration in Patients With Hepatobiliary Malignancy	Completed	NCT00698880	Phase 2, Phase 3
7	Percutaneous Bilateral Versus Unilateral Metal Stent Placement for Hilar Cholangiocarcinoma : A Prospective Open-label Randomized Controlled Trial	Recruiting	NCT02108145	Phase 2, Phase 3
8	Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine for Biliary Tract Cancer After Curative Resection	Recruiting	NCT03779035	Phase 3	Gemcitabine;Capecitabine
9	Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma	Terminated	NCT02082522	Phase 3	Photodynamic therapy-Photofrin;Chemotherapy regimen
10	Phase 1 Study of Liver Transplantation Combined With Neoadjuvant Radiochemotherapy for Unresectable Hilar Cholangiocarcinoma	Unknown status	NCT02178280	Phase 1, Phase 2
11	Photodynamic Therapy Using a Novel Photosensitizer in Locally Advanced Hilar Cholangiocarcinoma	Unknown status	NCT02725073	Phase 2
12	Downstaging of Unresectable Intrahepatic or Hilar Cholangiocellular Carcinoma by Selective Intra-arterial Floxuridine and Systemic Cisplatin and Gemcitabine. A Dose Finding Single Center Phase IIa Study	Completed	NCT01692704	Phase 1, Phase 2	Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin
13	Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma	Completed	NCT01093222	Phase 2	Erlotinib Hydrochloride;Sorafenib Tosylate
14	Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer	Completed	NCT02042443	Phase 2	Capecitabine;Fluorouracil;Leucovorin Calcium;Trametinib
15	Cholangiocarcinoma Detection Using an Intraoperative Fluorescence Image Guided Approach With Bevacizumab-IRDye 800CW	Recruiting	NCT03620292	Phase 1, Phase 2	Bevacizumab-IRDye800CW
16	A Phase IIA Study of ABC294640 in the Treatment of Patients With Advanced, Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma	Recruiting	NCT03377179	Phase 2	ABC294640
17	Safety and Tumoricidal Effect of Low Dose Temoporfin Photodynamic Therapy in Patients With Inoperable Bile Duct Cancers (Foscan® Study)	Recruiting	NCT03003065	Phase 2	Temoporfin
18	REGORAFENIB AFTER FAILURE OF GEMCITABINE AND PLATINUM-BASED CHEMOTHERAPY FOR LOCALLY ADVANCED (NON RESECTABLE) AND METASTATIC INTRA-HEPATIC OR HILAR CHOLANGIOCARCINOMA: A Randomized Double-blinded Phase II Trial.	Active, not recruiting	NCT02162914	Phase 2	Regorafenib/active;Regorafenib/placebo
19	Phase II Trial of Modified FOLFIRINOX in Patients With Metastatic Biliary Tract Cancer After Failure of Gemcitabine/Cisplatin Chemotherapy	Not yet recruiting	NCT03778593	Phase 2	5-Fluorouracil;Leucovorin;Irinotecan;Oxaliplatin
20	A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies	Not yet recruiting	NCT04068194	Phase 1, Phase 2	Avelumab;Nedisertib
21	Multi-center, Randomized, Controlled, Open-label Study of Deuteporfin Photodynamic Therapy Plus Stenting Versus Stenting Alone as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma	Terminated	NCT02955771	Phase 2
22	A Phase II Trial of LDK378 as the First or Second-line Therapy in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma	Terminated	NCT02374489	Phase 2	LDK378
23	Phase II Study of Stereotactic Body Radiotherapy (SBRT) and Chemotherapy for Unresectable Cholangiocarcinoma Followed by Liver Transplantation	Terminated	NCT01151761	Phase 2	Gemcitabine;Cisplatin;Carboplatin;Capecitabine;5FU
24	A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma	Terminated	NCT02254681	Phase 2	Gemcitabine;Cisplatin
25	Definitive Chemoradiation With Gemcitabine and Continuous 5- FU (Fluorouracil)Followed by High Dose Rate Brachytherapy or Stereotactic Body Radiation Therapy Boost in Locally Advanced Intra or Extrahepatic Cholangiocarcinoma	Terminated	NCT00983541	Phase 2	Fluorouracil (5-FU);Gemcitabine
26	A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Amphinex®-Induced Photochemical Internalisation (PCI) of Gemcitabine in Patients With Advanced Inoperable Cholangiocarcinomas	Completed	NCT01900158	Phase 1	Amphinex, Gemcitabine and Cisplatin
27	A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers	Completed	NCT01825603	Phase 1	ADH-1;Cisplatin;Gemcitabine Hydrochloride
28	Phase I Dose Escalation Trial of External Beam Radiation and Cyberknife Radiosurgery Boost With Concurrent Capecitabine for Hilar Cholangiocarcinoma (Klatskin Tumor)	Terminated	NCT00630890	Phase 1
29	A Phase Ib, Open-Label, Dose- Escalation Trial of ACY-1215 in Combination With Gemcitabine and Cisplatin in Patients With Unresectable or Metastatic Cholangiocarcinoma	Withdrawn	NCT02856568	Phase 1	Cisplatin;Gemcitabine Hydrochloride;Ricolinostat
30	Trapianto di Fegato Per Colangiocarcinoma (CCA) Ilare in Associazione a Radio e Chemioterapia Neoadiuvante	Unknown status	NCT01549795		Capecitabine
31	Superior Bilioenteric Anastomosis by Magnetic Compressive Technique: A Multicenter, Prospective, Randomized Controlled Trial	Unknown status	NCT02801500
32	Application of Endoscopic Scissors Cutting Endoscopic Nasobiliary Drainage Tube in the Treatment of Malignant Hilar Biliary Strictures: a Multicenter, Prospective, Randomized Controlled Study	Unknown status	NCT03353181
33	The Predictor of Infectious Complication After Hepatopancreatobiliary Surgery and Monitoring Indicator of Anti-infectious Therapy	Unknown status	NCT02878668
34	Optimization of Health Expenditure in Major Surgery: Impact of a Mixed, Clinical and Ethnographic Approach in the Model of Liver Surgery	Unknown status	NCT01715402
35	Exploratory Phase IV Randomized Single Blind Study Evaluating the Efficacy and Tolerability of Hemopatch in Improving Time of Hemostasis and Preventing Post-operative Complications After Hepatic Resection	Unknown status	NCT03323359
36	Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection?	Completed	NCT00733200
37	Long-term Morbidity After Surgery for Perihilar Cholangiocarcinoma; a Cohort Study	Completed	NCT03999593
38	Single Versus Multiple Deployment of Metallic Stents for Inoperable Malignant Hilar Biliary Obstruction: A Multicenter Prospective Randomized Study	Completed	NCT02166970
39	The Role of Gadoxetate Enhanced Spectral Dual-Energy CT in Evaluating Hilar Cholangiocarcinoma	Completed	NCT01673802	Early Phase 1	CT scan
40	Split-in-situ Resection With Radio-frequency Ablation Instead of Liver Partition on the First Stage (RALPPS) in Patients With Hilar and Intrahepatic Cholangiocarcinoma	Completed	NCT03320980
41	Photodynamic Therapy With Polyhematoporphyrin for Malignant Biliary Obstruction - a Retrospective Analysis.	Completed	NCT02504957
42	Best Biliary Drainage Option in Type II、III、IV Klatskin Tumor：ERCP or PTBD	Completed	NCT03104582
43	Observational Study for Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma	Completed	NCT01506115		Photofrin
44	Impact of Three-dimensional Visualization on Operation Strategy and Complications for Hilar Cholangiocarcinoma	Recruiting	NCT03132649
45	A Pilot Study to Determine the Feasibility of Stereotactic Body Radiation Therapy Following Chemotherapy for Unresectable Perihilar Cholangiocarcinoma. "The STRONG Trial"	Recruiting	NCT03307538
46	Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma: A Prospective Double-blind Multicenter Randomized Controlled Study	Recruiting	NCT03104569
47	Randomized Prospective Multicentric Study: Radio-chemotherapy and Liver Transplantation Versus Liver Resection to Treat Respectable Hilar Cholangiocarcinoma	Recruiting	NCT02232932
48	Effectiveness of Prophylactic Antibiotics to Prevent Post Endoscopic Retrograde Cholangio Pancreatography Bacteremia in Biliary Obstruction Patient	Recruiting	NCT02958059
49	Randomized Clinical Trial Comparing Three Dimension Laparoscopic and Open Surgery for Perihiliar Cholangiocarcinoma	Recruiting	NCT03383796
50	Expanded Access to ABC-108, A Phase IIA Study of ABC294640 in the Treatment of Patients With Advanced,Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma	Available	NCT03414489		ABC294640

Search NIH Clinical Center for Klatskin's Tumor

Cochrane evidence based reviews: klatskin tumor

Sources

Genetic Tests for Klatskin's Tumor

Sources

Anatomical Context for Klatskin's Tumor

MalaCards organs/tissues related to Klatskin's Tumor:

⁴⁰

Liver, Colon, B Cells, Ovary, Appendix, Lung, Testis

Sources

Publications for Klatskin's Tumor

Articles related to Klatskin's Tumor:

(show top 50) (show all 278)

#	Title	Authors	PMID	Year
1	Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma. ⁴⁶	Chen Y...Zou S	21165562	2011
2	Klatskin-mimicking neuroendocrine tumor. ⁶¹	Sanchez Fernandez MJ...Perez Fernandez A	31696723	2019
3	Acute mental change as the presenting sign of posthepatectomy hepatic failure: A case report. ⁶¹	Chon JY...Chung HS	31770264	2019
4	Percutaneous Hepaticojejunostomy across an Isolated Bile Duct after Klatskin Tumor Resection. ⁶¹	Desai H...Suhocki P	31349977	2019
5	Clinical features of isolated proximal-type immunoglobulin G4-related sclerosing cholangitis. ⁶¹	Takagi Y...Nakajima A	30570170	2019
6	Radiotherapy or Chemoradiation in Unresectable Biliary Cancer: A Retrospective Study. ⁶¹	Bisello S...Mattiucci GC	31177154	2019
7	Liver Transplant for Perihilar Cholangiocarcinoma (Klatskin Tumor): The Essential Role of Patient Selection. ⁶¹	Dondorf F...Rauchfu? F	29911960	2019
8	Klatskin Tumor: A Population-Based Study of Incidence and Survival. ⁶¹	Zhang X...Liu H	31204730	2019
9	Heterotopic chondroid tissue of the main bile duct mimicking Klatskin tumor: case report and review of the literature. ⁶¹	Dilek FH...Dilek ON	30499056	2019
10	Hepatic hilar mass in an adolescent: a rare case of hepatobiliary tuberculosis. ⁶¹	Pang L...Kong J	30832669	2019
11	Ultrasound-guided percutaneous irreversible electroporation of hepatic and abdominal tumors not eligible for surgery or thermal ablation: a western report on safety and efficacy. ⁶¹	Giorgio A...Giorgio V	30843171	2019
12	Primary large cell neuroendocrine carcinoma of the common hepatic duct mimicking a Klatskin tumor. ⁶¹	Koo JY...Kim TN	29466852	2019
13	Klatskin tumors and "Klatskin-mimicking lesions": our 22-year experience. ⁶¹	Tsalis K...Angelopoulos S	30421957	2019
14	Concomitant adenosquamous carcinoma and cystadenocarcinoma of the extrahepatic bile duct: A case report. ⁶¹	Lu BJ...Sun MY	30705898	2019
15	Preoperative Portal Vein Embolization Alone with Biliary Drainage Compared to a Combination of Simultaneous Portal Vein, Right Hepatic Vein Embolization and Biliary Drainage in Klatskin Tumor. ⁶¹	Hocquelet A...Denys A	30238334	2018
16	[Cavernoma complicated with biliopatia secondary to type 1 Gaucher disease: report of a Peruvian case]. ⁶¹	Moran-Marinos C...Quispe-Colquepisco S	30540732	2018
17	IgG4-related sclerosing cholangitis mimicking hilar cholangiocarcinoma (Klatskin tumor): a case report of a challenging disease and review of the literature. ⁶¹	Mittelstaedt A...Jaehne J	31579779	2018
18	Patient With Unresectable Cholangiocarcinoma Treated With Radiofrequency Hyperthermia in Combination With Chemotherapy: A Case Report. ⁶¹	Ryu J...Yoo HS	28745084	2018
19	Gerald Klatskin (1910-1986): A pioneer in hepato-biliary disorders and biopsy techniques. ⁶¹	Ramai D...Reddy M	29998747	2018
20	Metastatic Pancreatic Adenocarcinoma Presenting as a Klatskin Tumor. ⁶¹	Munis A...Mahdavian M	30568968	2018
21	[Cholangiocellular cancer: the state of the problem and ways to improve the results of surgical treatment]. ⁶¹	Patyutko YI...Pokataev IA	30560842	2018
22	Mirizzi Syndrome: Diagnosis and Management of a Challenging Biliary Disease. ⁶¹	Clemente G...Giuliante F	30159303	2018
23	Klatskin Tumor. ⁶¹	Siriwardena AK	28985102	2017
24	Best option for preoperative biliary drainage in Klatskin tumor: A systematic review and meta-analysis. ⁶¹	Tang Z...Li X	29069029	2017
25	Hepatoduodenal lymph node metastasis mimicking Klatskin tumor in a patient with sigmoid colon mucinous cancer. ⁶¹	Vardevanyan H...Forstner R	28828110	2017
26	Single synchronous liver metastasis from Merkel cell carcinoma mimicking a klatskin tumor: A diagnostic challenge. ⁶¹	Vennarecci G...Ettorre GM	28473299	2017
27	Preoperative biliary drainage versus direct surgery for perihilar cholangiocarcinoma: A retrospective study at a single center. ⁶¹	Cai Y...Cheng N	28529266	2017
28	Primary Hepatic Lymphoma Mimicking Cholangiocarcinoma. ⁶¹	Forghani F...Kadivar M	28804587	2017
29	Primary extrahepatic bile duct neuroendocrine tumor with obstructive jaundice masquerading as a Klatskin tumor. ⁶¹	Hoepfner L...White JA	28596824	2017
30	Evaluation of Tumor Markers and Their Impact on Prognosis in Gallbladder, Bile Duct and Cholangiocellular Carcinomas - A Pilot Study. ⁶¹	Liska V...Holubec L	28373474	2017
31	Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications. ⁶¹	Dolak W...Austrian PDT study group	28405328	2017
32	Mortality after portal vein embolization: Two case reports. ⁶¹	Lee EC...Kim HB	28178122	2017
33	Extrahepatic biliary obstrution secondary to neuroendocrine tumor of the common hepatic duct. ⁶¹	Khan FA...Weaver D	27902955	2017
34	Best options for preoperative biliary drainage in patients with Klatskin tumors. ⁶¹	Jo JH...Chung JB	27287904	2017
35	Bilateral ovarian metastasis of a Klatskin tumor: A rare case. ⁶¹	Kurt S...Astarcioglu I	28913125	2016
36	A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer. ⁶¹	Lee KJ...Park SW	27586966	2016
37	Associating Liver Partition and Portal Vein Ligation for Primary Hepatobiliary Malignancies and Non-Colorectal Liver Metastases. ⁶¹	Bjornsson B...Sandstrom P	26929296	2016
38	Isolated Liver Hilar Infiltration by IgG4 Inflammation Mimicking Cholangiocarcinoma. ⁶¹	Bochatay L...Frossard JL	27843427	2016
39	The Klatskin Tumor That Wasn't: An Unusual Presentation of Sarcoidosis. ⁶¹	Farooq PD...Potosky DR	27761479	2016
40	Y-configured metallic stent combined with (125)I seed strands cavity brachytherapy for a patient with type IV Klatskin tumor. ⁶¹	Dechao J...Zhen L	27648091	2016
41	Palliative Locoregional Treatment for Unresectable Nonmetastatic Klatskin Tumor: Percutaneous Transhepatic Biliary Drainage Combined With 3-dimensional Conformal Radiotherapy. ⁶¹	Liu Y...Zhang Z	27035079	2016
42	[Operation treatment method of Bismuth-Corlette Ⅲ, Ⅳ hilar cholangiocarcinoma]. ⁶¹	Lu Z...Wang DD	27373472	2016
43	[Klatskin tumor: long-term survival following surgery]. ⁶¹	Juntermanns B...Kaiser GM	27090415	2016
44	Endobronchial Watanabe Spigot in the treatment of bronchobiliary fistula. ⁶¹	Ozdemir C...Dalar L	27374219	2016
45	Atypical presentation of a hepatic artery pseudoaneurysm: A case report and review of the literature. ⁶¹	Luckhurst CM...Trevino JG	27366305	2016
46	Stent placement above the sphincter of Oddi permits implementation of neoadjuvant chemotherapy in patients with initially unresectable Klatskin tumor. ⁶¹	Kubota K...Endo I	27092322	2016
47	Percutaneous "Y" biliary stent placement in palliative treatment of type 4 malignant hilar stricture. ⁶¹	Corvino F...Bencivenga A	27034794	2016
48	Neuroendocrine Carcinoma of the Gallbladder Masquerading as a Klatskin Tumor in a 74-Year-Old Male. ⁶¹	Kutting F...Steffen HM	26036328	2016
49	[Klatskin tumor - a case report]. ⁶¹	Iwaniec-Karlikowska E...Grys I	27000815	2016
50	[Percutaneous cholangiostomy for portal cholangiocarcinoma]. ⁶¹	Okhotnikov OI...Pakhomov VI	27723691	2016

Sources

Genes for Klatskin's Tumor

Genes related to Klatskin's Tumor (1 elite genes):

(show all 18)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	MIR373	MicroRNA 373	RNA Gene	355.63	Causal ⁴⁶ DISEASES inferred ¹⁵	21165562
2	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	150	Experimental evidence: Regulation ³⁸	28059437
3	MACC1	MET Transcriptional Regulator MACC1	Protein Coding	12.26	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	MMP9	Matrix Metallopeptidase 9	Protein Coding	12.14	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	MMP2	Matrix Metallopeptidase 2	Protein Coding	11.83	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	MMP14	Matrix Metallopeptidase 14	Protein Coding	10.86	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	APC	APC Regulator Of WNT Signaling Pathway	Protein Coding	7.76	GeneCards inferred via : Variants (show sections)
8	PRR11	Proline Rich 11	Protein Coding	6.95	DISEASES inferred ¹⁵
9	PCCA	Propionyl-CoA Carboxylase Subunit Alpha	Protein Coding	6.65	DISEASES inferred ¹⁵
10	PTPRE	Protein Tyrosine Phosphatase Receptor Type E	Protein Coding	6.57	DISEASES inferred ¹⁵
11	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	6.56	DISEASES inferred ¹⁵
12	PRRT2	Proline Rich Transmembrane Protein 2	Protein Coding	6.45	DISEASES inferred ¹⁵
13	SLC38A1	Solute Carrier Family 38 Member 1	Protein Coding	6.16	DISEASES inferred ¹⁵
14	MBD2	Methyl-CpG Binding Domain Protein 2	Protein Coding	5.88	DISEASES inferred ¹⁵
15	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	5.83	DISEASES inferred ¹⁵
16	AFP	Alpha Fetoprotein	Protein Coding	5.78	DISEASES inferred ¹⁵
17	KRT7	Keratin 7	Protein Coding	5.77	DISEASES inferred ¹⁵
18	ALB	Albumin	Protein Coding	5.76	DISEASES inferred ¹⁵

Sources

Variations for Klatskin's Tumor

ClinVar genetic disease variations for Klatskin's Tumor:

⁶ ‎‎

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	GRCh37 Pos	GRCh38 Pos
1	APC	NM_000038.6(APC):c.4658C>T (p.Ala1553Val)	SNV	Uncertain significance	559953	rs1554086050	5:112175949-112175949	5:112840252-112840252

Sources

Expression for Klatskin's Tumor

Search GEO for disease gene expression data for Klatskin's Tumor.

Sources

Pathways for Klatskin's Tumor

Pathways related to Klatskin's Tumor according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Matrix Metalloproteinases ¹ Show member pathways Activation of Matrix Metalloproteinases ⁶⁵ Inhibition of Matrix Metalloproteinases ⁶³	11.54	MMP9 MMP2 MMP14
2	Colorectal Cancer Metastasis ⁶³	11.47	MMP9 MMP2 MMP14 APC
3	Regulation of Wnt-mediated beta catenin signaling and target gene transcription ¹	11.4	MMP9 MMP2 APC
4	AGE/RAGE pathway ¹	11.25	MMP9 MMP2 MMP14
5	Cell adhesion_ECM remodeling ²²	11.12	MMP9 MMP2 MMP14
6	Adhesion ⁴	11.01	MMP9 MMP2 MMP14 CEACAM5

Sources

GO Terms for Klatskin's Tumor

Biological processes related to Klatskin's Tumor according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	response to amyloid-beta	GO:1904645	9.37	MMP9 MMP2
2	extracellular matrix disassembly	GO:0022617	9.33	MMP9 MMP2 MMP14
3	tissue remodeling	GO:0048771	9.32	MMP2 MMP14
4	transport	GO:0006810	9.26	ALB AFP
5	collagen catabolic process	GO:0030574	9.13	MMP9 MMP2 MMP14
6	endodermal cell differentiation	GO:0035987	8.8	MMP9 MMP2 MMP14

Molecular functions related to Klatskin's Tumor according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	metalloendopeptidase activity	GO:0004222	8.8	MMP9 MMP2 MMP14

Sources

Sources for Klatskin's Tumor

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia